ArticleMicrosystems & nanoengineering2026
Micro pharmacokinetics-pharmacodynamics monitoring of anti-Parkinson's disease drugs using a microphysiological BBB-brain organ-on-a-chip.
Article in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Establishing robust pharmacokinetics-pharmacodynamics (PK-PD) correlations remains a major challenge owing to high selectivity and low permeability of the blood-brain barrier (BBB), which limits the predictive power of conventional plasma pharmacokinetics on specific brain tissue. Here, we present a highly biomimetic microfluidic BBB-brain organ-on-a-chip combined with liquid chromatography-mass spectrometry (LC-MS) and electrochemical sensing technology for micro PK-PD monitoring with target cells. The platform incorporates human cerebral microvascular endothelial cells and neuron-like cells cultured on opposite sides of a collagen/fibronectin-modified porous membrane under physiological shear stress. This configuration reinforces the physical, metabolic and physiological barrier functions of BBB, as evidenced by the high expression of tight junction proteins, low apparent permeability, expression of efflux transporters, and reversible response to hypertonic stimuli. A neurodegenerative disease model is induced using 1-methyl-4-phenylpyridinium iodide (MPP
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.